Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US58933Y1055
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000BPD168
MRK
Merck & Co Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Drug Manufacturers—General · THEMEFOLIO: $TF-77
NAME
Merck & Co Inc
ISIN
US58933Y1055
TICKER
MRK
MIC
XNYS
REUTERS
MRK.N
BLOOMBERG
MRK US
Thu, 19.02.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive second RSV season findings from the Phase 3 SMART trial (MK-1654-007) (NCT04938830) evaluating the safety, efficacy and pharmacokinetics of ENFLONSIA™ (clesrovimab) in infants and children at increased risk for severe respiratory syncytial virus (RSV)...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.02.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the U.S. and Canada, and Mayo Clinic, the world's top-ranked hospital system, today announced a research and development agreement to apply artificial intelligence (AI), advanced analytics and multimodal clinical data to support drug discovery and development. The agreement integrates Mayo Clinic's Platfo...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.02.2026       Merck & Co.
US58933Y1055

KIRKLAND, QC, Feb. 17, 2026 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA SC™ (pembrolizumab injection), a new subcutaneous formulation of pembrolizumab, Merck's anti–PD-1 therapy....
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.02.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that data across multiple genitourinary cancers from several approved and investigational medicines will be presented at the 2026 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium from Feb. 26-28. These data, including three studi...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.02.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) plus paclitaxel, with or without bevacizumab, for the treatment of adults with PD-L1+ (Combined Positive Score [CP...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.02.2026       Merck & Co.
US58933Y1055

Approval is based on the CLEVER and SMART Clinical Trial ResultsKIRKLAND, QC, Feb. 5, 2026 /CNW/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Health Canada has approved ENFLONSIA® (clesrovimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newbo...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.02.2026       Merck & Co.
US58933Y1055

Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2025. "In 2025, we continued to advance leading-edge science to deliver transformative medicines and vaccines that are improving health outcomes for patients around the...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.01.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company’s common stock for the second quarter of 2026. Payment will be made on April 7, 2026, to shareholders of record at the close of business on March 16, 2026. About...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.01.2026       Merck & Co.
US58933Y1055

Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Jan. 27, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The global oncology therapy market is charging toward a massive $668 billion valuation by 2034, as a ruthless capital rotation finally rewards execution-ready platforms over the "hopes and dreams" of speculative discovery as...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Tue, 27.01.2026       Merck & Co.
US58933Y1055

Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Jan. 27, 2026 /CNW/ -- Equity-Insider.com News Commentary – The global oncology therapy market is charging toward a massive $668 billion valuation by 2034, as a ruthless capital rotation finally rewards execution-ready platforms over the "hopes and dreams" of speculative discovery assets[1]...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 07.01.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a Phase 3 clinical trial evaluating calderasib (MK-1084), an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) for the first-line treatment of...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.01.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all the outstanding shares of common stock of Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”). “The acquisition of Cidara strengthens and complements our expanding respiratory...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.01.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, Feb. 3. During the call, company executives will provide an overview of Merck’s performance for the quarter. Investors, j...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Mon, 05.01.2026       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference on Monday,...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Fri, 19.12.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced a historic agreement with the Trump administration to ensure its prescription medicines are both accessible and affordable for Americans. This agreement enables Merck to continue its long-standing commitment to develop and deliver life-changing medicines and v...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Wed, 17.12.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. The trial showed KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedot...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Sun, 14.12.2025       Merck & Co.
US58933Y1055

Das Instrument 6MK US58933Y1055 MERCK CO. DL-,01 EQUITY wird ex Dividende/Zinsen gehandelt am 15.12.2025 The instrument 6MK US58933Y1055 MERCK CO. DL-,01 EQUITY has its ex-dividend/interest day on 15.12.2025...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.12.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the approval of an expanded indication for WINREVAIR™ (sotatercept), in combination with other pulmonary arterial hypertension (PAH) therapies, for the treat...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.12.2025       Merck & Co.
US58933Y1055

Das Instrument 6MK US58933Y1055 MERCK CO. DL-,01 EQUITY wird cum Dividende/Zinsen gehandelt am 12.12.2025 und ex Dividende/Zinsen am 15.12.2025 The instrument 6MK US58933Y1055 MERCK CO. DL-,01 EQUITY has its pre-dividend/interest day on 12.12.2025 and its ex-dividend/interest day on 15.12.2025...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.12.2025       Merck & Co.
US58933Y1055

KIRKLAND, QC, Dec. 8, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the province of Saskatchewan has added CAPVAXIVE®, a 21-valent pneumococcal conjugate vaccine, to its publicly funded adult immunization program. This addition supports increased access to pneumococcal immunization for eli...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 04.12.2025       Merck & Co.
US58933Y1055

Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) has granted a conditional approval for EXZOLT™ CATTLE-CA1 (fluralaner topical solution). This innovative product is in the newest cla...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.12.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present first-in-human data for MK-2214 and MK-1167 at Clinical Trials on Alzheimer’s Disease (CTAD) 2025 in San Diego, California from Dec. 1-4. In addition, the company announced that MK-2214, a novel candidate targeting the abnormal accumulation an...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.11.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Chirfi Guindo, chief marketing officer, Human Health, and Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Citi 2025 G...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.11.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Chirfi Guindo, chief marketing officer, Human Health, and Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, are scheduled to participate in a fireside chat at the 8th Annual...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Mon, 24.11.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla. from Dec. 6-9. The data shared at the meeting will highlight the company’s ongoing commitment to...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Sat, 22.11.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside the United States and Canada, has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited “mini-tender” offer, dated November 10, 2025, to purchase up to 1,000,000 shares of Merck common stock at $65.00 per share. The offer price is approximately 24.66% below the closing price of Merck common...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Fri, 21.11.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.11.2025       Merck & Co.
US58933Y1055

KIRKLAND, QC, Nov. 20, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that it has successfully completed negotiations with the pan‑Canadian Pharmaceutical Alliance (pCPA) for WINREVAIR® (sotatercept). The pCPA negotiates on behalf of the provinces, territories, an...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.11.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal double-blind Phase 3 trial of the investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg)] in adults with HIV-1 infection who had not previously received antiretrovi...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Wed, 19.11.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved a new subcutaneous (SC), or under the skin, route of administration and a new pharmaceutical form (solution for injection) of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. KEYTRUDA SC™, as it will be marke...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.11.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company’s common stock for the first quarter of 2026. Payment will be made on Jan. 8, 2026, to shareholders of record at the close of business on Dec. 15, 2025. About Mer...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.11.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 2 CADENCE study evaluating WINREVAIR™ (sotatercept-csrk) in adults for the treatment of combined post- and precapillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF). CADENC...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Fri, 14.11.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221....
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.11.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., and Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Jefferies Global Healthca...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Sun, 09.11.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef HeFH trial demonstrating that treatment with enlicitide decanoate, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, resulted in a statistic...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Sat, 08.11.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef Lipids trial demonstrating that treatment with enlicitide decanoate, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, resulted in a statist...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.11.2025       Merck & Co.
US58933Y1055

KIRKLAND, QC, Nov. 5, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the province of Quebec has added CAPVAXIVE®, a 21-valent pneumococcal conjugate vaccine, to their publicly funded adult immunization program. This addition makes the vaccine available...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.11.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has entered into an agreement to receive funds managed by Blackstone Life Sciences (“Blackstone”) for the development of sacituzumab tirumotecan (sac-TMT), an investigational antibody-drug conjugate (ADC) targeting trophoblast cell-surface ant...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.11.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the company, through a subsidiary (Prometheus BioSciences), has reached an agreement with Dr. Falk Pharma GmbH (Falk) to discontinue an existing contract concerning co-development and co-commercialization rights in certain territories for MK-8690 (formerl...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.11.2025       Merck & Co.
US58933Y1055

The Merck Foundation announced today the launch of the Collaborative for Equity in Cardiac Care, a $22 million, five-year initiative aimed at enhancing access to high-quality, person-centered health care for people living with heart conditions in the U.S. Eleven organizations are receiving grants to support the development and implementation of ev...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.10.2025       Merck & Co.
US58933Y1055

Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2025. “In the third quarter, we continued to execute on our strategy with important pipeline advancements, significant approvals and successful new product launches,” said Robert M. D...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.10.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LEAP-012 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, in combination with trans...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.10.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as monotherapy for the treatment of resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC) as neoadjuvant treatment, continued as adjuvan...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.10.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 LITESPARK-022 trial in patients with clear cell renal cell carcinoma (RCC) following nephrectomy. In this study, KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with WELIREG® (belzutifan), Merck’s...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.10.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced that the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG® (belzutifan), Merck’s first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus LENVIMA® (lenvatinib), an orally available multiple receptor tyrosin...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.10.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. product label based on the Phase 3 ZENITH trial for WINREVAIR™ (sotatercept-csrk) for injection, 45mg, 60mg. WINREVAIR, an activin signaling inhibitor, is now FDA-approved for the...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.10.2025       Merck & Co.
US58933Y1055

BOSTON, Oct. 23, 2025 /PRNewswire/ -- eschbach is pleased to share that Merck (NYSE: MRK), known as MSD outside the United States and Canada, has selected Shiftconnector to improve how it uses digital tools in manufacturing. By integrating Shiftconnector into its established visual factory framework, Merck is enh...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.10.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from the company’s cardio-pulmonary portfolio and pipeline at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, La., from November 7–10. Data presented at AHA highlight Merck’s continued dedication to a...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.10.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for two supplemental Biologics License Applications (sBLA) for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with P...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.10.2025       Merck & Co.
US58933Y1055

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of findings from a systematic literature review of studies on the epidemiology and antimicrobial resistance (AMR) of pneumococcal serotypes covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. adults. The evaluation examine...
Read more
Merck & Co.
Technical Analysis Termsheets Terminal
Permalink